Diffuse large B-cell lymphoma (DLBCL) was considered an incurable disease until the introduction of polychemotherapy (e.g., CHOP) in the 1970s. Treatment improved significantly with the introduction of the anti-CD20 antibody, rituximab, in combination with CHOP (R-CHOP), however, one-third of patients are either refractory to this initial treatment or relapse after treatment. Prof Laurie Sehn chaired a symposium as part of the 15th International Congress on Malignant Lymphoma (ICML) in Lugano, Switzerland, discussing the unmet need of DLBCL patients and the future of using antibody therapy.
